These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 27213997)

  • 1. A survey on the medication adherence to methotrexate among rheumatoid arthritis patients treated with self-administered biologic drugs.
    Aaltonen KJ; Turunen JH; Sokka T; Puolakka K; Valleala H
    Clin Exp Rheumatol; 2016; 34(4):694-7. PubMed ID: 27213997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.
    Shimizu Y; Tanaka E; Inoue E; Shidara K; Sugimoto N; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
    Mod Rheumatol; 2018 May; 28(3):461-467. PubMed ID: 28880684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary methotrexate dosage in rheumatoid arthritis, in patients treated for at least 6 months: a potential marker of adherence.
    Théate N; Geoffroy M; Kanagaratnam L; Gozalo C; Charlot I; Bolko L; Hittinger-Roux A; Djerada Z; Salmon JH
    RMD Open; 2024 May; 10(2):. PubMed ID: 38772677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
    Müller RB; von Kempis J; Haile SR; Schiff MH
    Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perceptions of methotrexate use in rheumatoid arthritis by rheumatologists and their patients: an Australian survey study.
    Nash P; Nicholls D
    Int J Rheum Dis; 2013 Dec; 16(6):652-61. PubMed ID: 24382276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of disease-modifying anti-rheumatic drugs and clinical outcomes in the Rheumatoid Arthritis DMARD Intervention and Utilisation Study 2 (RADIUS 2).
    Gibofsky A; Cannon GW; Harrison DJ; Joseph GJ; Bitman B; Chaudhari S; Collier DH
    Clin Exp Rheumatol; 2015; 33(3):297-301. PubMed ID: 25738333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population.
    Jones G; Hall S; Bird P; Littlejohn G; Tymms K; Youssef P; Chung E; Barrett R; Button P
    Int J Rheum Dis; 2018 Aug; 21(8):1581-1590. PubMed ID: 29205926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: a multicentre, non-interventional study.
    Calvo-Alén J; Monteagudo I; Salvador G; Vázquez-Rodríguez TR; Tovar-Beltrán JV; Vela P; Maceiras F; Bustabad S; Román-Ivorra JA; Díaz-Miguel C; Rosas J; Raya E; Carmona L; Cea-Calvo L; Arteaga MJ; Fernández S; Marras C
    Clin Exp Rheumatol; 2017; 35(3):423-430. PubMed ID: 28032846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of methotrexate adherence in rheumatoid arthritis patients.
    De Cuyper E; De Gucht V; Maes S; Van Camp Y; De Clerck LS
    Clin Rheumatol; 2016 May; 35(5):1335-9. PubMed ID: 26781783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.
    Lie E; van der Heijde D; Uhlig T; Heiberg MS; Koldingsnes W; Rødevand E; Kaufmann C; Mikkelsen K; Kvien TK
    Ann Rheum Dis; 2010 Apr; 69(4):671-6. PubMed ID: 19740904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry.
    Narongroeknawin P; Chevaisrakul P; Kasitanon N; Kitumnuaypong T; Mahakkanukrauh A; Siripaitoon B; Katchamart W;
    Int J Rheum Dis; 2018 Jan; 21(1):170-178. PubMed ID: 28737837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication adherence and cost-related medication non-adherence in patients with rheumatoid arthritis: A cross-sectional study.
    Heidari P; Cross W; Weller C; Nazarinia M; Crawford K
    Int J Rheum Dis; 2019 Apr; 22(4):555-566. PubMed ID: 30924291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the adherence to disease-modifying drugs in patients with chronic inflammatory rheumatic diseases: Results of a survey of 1594 patients.
    López-Medina C; Moltó A; Gérald F; Dubremetz M; Grange L; Thibaud G; Charles B; Lafarge D; Beauvais C; Gossec L; Dougados M
    Joint Bone Spine; 2019 Oct; 86(5):610-614. PubMed ID: 30738192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study.
    Mena-Vazquez N; Manrique-Arija S; Yunquera-Romero L; Ureña-Garnica I; Rojas-Gimenez M; Domic C; Jimenez-Nuñez FG; Fernandez-Nebro A
    Rheumatol Int; 2017 Oct; 37(10):1709-1718. PubMed ID: 28631046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
    Agarwal S; Zaman T; Handa R
    Singapore Med J; 2009 Jul; 50(7):686-92. PubMed ID: 19644623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register.
    Bechman K; Oke A; Yates M; Norton S; Dennison E; Cope AP; Galloway JB
    Rheumatology (Oxford); 2020 Sep; 59(9):2563-2571. PubMed ID: 31998962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden.
    Kristensen LE; Saxne T; Nilsson JA; Geborek P
    Arthritis Res Ther; 2006; 8(6):R174. PubMed ID: 17121678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BeSt way of withdrawing biologic agents.
    Allaart CF; Lems WF; Huizinga TW
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S14-8. PubMed ID: 24129130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study.
    Moura CS; Abrahamowicz M; Beauchamp ME; Lacaille D; Wang Y; Boire G; Fortin PR; Bessette L; Bombardier C; Widdifield J; Hanly JG; Feldman D; Maksymowych W; Peschken C; Barnabe C; Edworthy S; Bernatsky S;
    Arthritis Res Ther; 2015 Aug; 17(1):197. PubMed ID: 26235697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single nucleotide polymorphism of reduced folate carrier 1 predicts methotrexate efficacy in Japanese patients with rheumatoid arthritis.
    Hayashi H; Tazoe Y; Tsuboi S; Horino M; Morishita M; Arai T; Ohshima M; Matsuyama T; Kosuge K; Yamada H; Tsuji D; Inoue K; Itoh K
    Drug Metab Pharmacokinet; 2013; 28(2):164-8. PubMed ID: 22971639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.